

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6015643

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
GANYMED PHARMACEUTICALS GMBH	11/26/2019
RECEIVING PARTY DATA	
Name:	BIONTECH SE
Street Address:	AN DER GOLDGRUBE 12
City:	MAINZ
State/Country:	GERMANY
Postal Code:	55131
PROPERTY NUMBERS Total: 8	
Property Type	Number
Patent Number:	7429461
Patent Number:	8716455
Patent Number:	8551490
Patent Number:	9453260
Patent Number:	10414824
Patent Number:	9090940
Patent Number:	10036753
Patent Number:	9637548
CORRESPONDENCE DATA	
Fax Number:	(312)775-8100
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3127758000
Email:	mhmpto@mcandrews-ip.com
Correspondent Name:	MCANDREWS, HELD & MALLOY, LTD.
Address Line 1:	500 W. MADISON STREET
Address Line 2:	SUITE 3400
Address Line 4:	CHICAGO, ILLINOIS 60661
ATTORNEY DOCKET NUMBER:	16034US01,US03,US04,US06,
NAME OF SUBMITTER:	JENNA T. MAZZONI
SIGNATURE:	/Jenna T. Mazzoni/

PATENT

DATE SIGNED:	03/16/2020
---------------------	------------

Total Attachments: 5

source=Assignment Ganymed GMBH_BioNTech#page1.tif

source=Assignment Ganymed GMBH_BioNTech#page2.tif

source=Assignment Ganymed GMBH_BioNTech#page3.tif

source=Assignment Ganymed GMBH_BioNTech#page4.tif

source=Assignment Ganymed GMBH_BioNTech#page5.tif

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT ("Assignment") is made by Ganymed Pharmaceuticals GmbH, a German corporation, at An der Goldgrube 12, 55131 Mainz, Germany ("Assignor"), and BioNTech SE, at An der Goldgrube 12, Mainz Germany, 55131 ("Assignee").

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt, adequacy, and sufficiency of which are hereby acknowledged:

Assignor hereby assigns to Assignee, its successors and assigns, one hundred percent (100%) of its right, title and interest in and to the inventions and improvements disclosed in **Schedule A**, and in any and all other (provisional or non-provisional) applications in the United States based thereon or that claim priority thereto, including any continuation, continuation-in-part, divisional application that the Assignor may file, either solely or jointly with others, and in any and all Letters Patent of the United States that may be obtained on any of said applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents. The Assignor further recognizes and assigns to said Assignee a priority right provided by the International Convention, treaties or otherwise.

The Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks to issue said Letters Patent in the name of the Assignee.

Assignor and Assignee each hereby mutually covenant and agree to reasonably cooperate in order to enjoy the right, title and interest in and to said inventions or improvements. Such reasonable cooperation shall include execution of any and all continuation, continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination or extension of any Letters Patent that may be granted upon said application, and any and all applications and other document for Letters Patent on said invention or improvements. The Assignor and the Assignee further hereby mutually covenant and agree to cooperate in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent in the United States, and vest all rights therein hereby conveyed in the Assignor and the Assignee, each of their successors and assigns.

This Assignment shall be binding upon and shall inure to the benefit of Assignee and Assignor and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

[SIGNATURE PAGE FOLLOWS]

ASSIGNOR:
Ganymed Pharmaceuticals GmbH


By: _____
Name: Kevin Miles
Title: General Manager

WITNESSED by _____ this _____ day of _____, 2019.

WITNESSED by _____ this _____ day of _____, 2019.

Acknowledged and agreed:

ASSIGNEE:
BioNTech SE

By: 
Name: Dr. Sieck Foetting
Title: Managing Board

WITNESSED by Elinabeth Miklas this 03 day of December 2019.

WITNESSED by Wilfgang Riecher this 03 day of December 2019.

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT ("Assignment") is made by Ganymed Pharmaceuticals GmbH, a German corporation, at An der Goldgrube 12, 55131 Mainz, Germany ("Assignor"), and BioNTech SE, at An der Goldgrube 12, Mainz Germany, 55131 ("Assignee").

NOW, THEREFORE, in exchange for good and valuable consideration, the receipt, adequacy, and sufficiency of which are hereby acknowledged:

Assignor hereby assigns to Assignee, its successors and assigns, one hundred percent (100%) of its right, title and interest in and to the inventions and improvements disclosed in **Schedule A**, and in any and all other (provisional or non-provisional) applications in the United States based thereon or that claim priority thereto, including any continuation, continuation-in-part, divisional application that the Assignor may file, either solely or jointly with others, and in any and all Letters Patent of the United States that may be obtained on any of said applications, and in any reexamination, renewal, substitution, reissue or extension of such applications or patents. The Assignor further recognizes and assigns to said Assignee a priority right provided by the International Convention, treaties or otherwise.

The Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks to issue said Letters Patent in the name of the Assignee.

Assignor and Assignee each hereby mutually covenant and agree to reasonably cooperate in order to enjoy the right, title and interest in and to said inventions or improvements. Such reasonable cooperation shall include execution of any and all continuation, continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination or extension of any Letters Patent that may be granted upon said application, and any and all applications and other document for Letters Patent on said invention or improvements. The Assignor and the Assignee further hereby mutually covenant and agree to cooperate in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent in the United States, and vest all rights therein hereby conveyed in the Assignor and the Assignee, each of their successors and assigns.

This Assignment shall be binding upon and shall inure to the benefit of Assignee and Assignor and their respective successors and assigns.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

[SIGNATURE PAGE FOLLOWS]

ASSIGNOR:
Ganymed Pharmaceuticals GmbH

By: _____
Name: Kevin Miles
Title: General Manager

WITNESSED by _____ this 26 day of 11, 2019.

WITNESSED by _____ this 26 day of 11, 2019.

Acknowledged and agreed:

ASSIGNEE:
BioNTech SE

By: _____
Name:
Title:

WITNESSED by _____ this _____ day of _____, 2019.

WITNESSED by _____ this _____ day of _____, 2019.

SCHEDULE A

Patent/Application No.	Attorney Docket No.	Filing Date
7429461	16034US01	2004-09-02
8716455	16034US03	2008-08-25
8551490	16034US04	2011-07-18
9453260	16034US06	2014-05-02
15/650092	19964US07	2017-07-14
8765389	24857US01	2006-03-10
9090940	24858US01	2009-02-19
10036753	24858US03	2015-06-19
9637548	20506US02	2011-08-29